Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution
- 1 November 1992
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 66 (11) , 6777-80
- https://doi.org/10.1128/jvi.66.11.6777-6780.1992
Abstract
The third variable domain (V3) of the human immunodeficiency virus type 1 external envelope contains determinants of cell tropism, cytopathicity, and infectivity and elicits antibodies able to block infectivity in vitro and in vivo. Our study encompassed point-mutational analysis of HXB-2 viruses containing patient-derived V3 regions and expressing a non-syncytium-inducing, low-replicating phenotype in T-cell line SupT1. The mutation within V3 of a serine at position 306 into an also naturally occurring arginine (S to R) required an additional, naturally occurring mutation at position 320 (aspartate to glutamine, D to Q) or 324 (aspartate to asparagine, D to N) for full expression of the syncytium-inducing, high-replicating (SI) phenotype. The naturally occurring mutation of an aspartate into an arginine at position 320 (D to R) was sufficient for production of the SI phenotype. This study proves that introduction of a positively charged amino acid at position 306 or 320, previously shown to be strongly associated with the SI phenotype in field isolates (R.A.M. Fouchier, M. Groenink, N.A. Kootstra, M. Tersmette, H.G. Huisman, F. Miedema, and H. Schuitemaker, J. Virol. 66:3183-3187, 1992), is minimally required for production of SI viruses. In addition, naturally occurring mutations at residue 324 also modulate the virus phenotype.Keywords
This publication has 11 references indexed in Scilit:
- Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotypeJournal of Virology, 1992
- Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 moleculeJournal of Virology, 1992
- Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralizationJournal of Virology, 1992
- Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacityJournal of Virology, 1992
- Identification of the Envelope V3 Loop as the Primary Determinant of Cell Tropism in HIV-1Science, 1991
- Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 geneNature, 1991
- Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domainJournal of Virology, 1991
- HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domainNature, 1990
- Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolatesJournal of Virology, 1989
- ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITYThe Lancet, 1989